posted
"She just lacks tact and apparently could care less about that."
This is correct.
Hard to imagine my writing,
"Hello my dear friends. I am a decent and honest trader just like you. I truly care about all who read my articles. I am here to help. I would very much appreciate your buying this stock so you can profit and so I can also make a small profit. Do consider, if you would be so kind, buying this stock so all of us can make profits. My goal is sincerely to help all of you profit and, in turn, make a little profit, as well. Please buy this stock to help all of us profit."
As if...
Boy, do not you tire of reality b!tch slapping you?
Oh sure, let's all play nice-nice because all here are decent, honest, trustworthy people who never entertain a notion of stealing away your money.
Good board guys.My 2 cents worth FWIW.I fully agree with the posts recognizing that XKEM is being heavily manipulated.The other day as it .078 and was at .075 to test .08 again I placed a large purchaes order at .045 the rest you know...it hit .043 and turned! I was beneficiary of an excellent entry with those .045 shares because I was looking for the next harsh,manipulative dip that I guessed to bottom not lower than .041.!Today...while hovering yet again in across .10 I placed my purchase for more shares at .073 but we ran out of market as these crooks did their thing.But take note of this...after the dip to .043 the run to .115 today was the net result!If MMs are as short as I think then the news today forced them to drop it like a rock...it was excellent news.dont ever forget...it is the MM that sets the bid/ask and it is the MMs that can legally short to suit their agendas.I place no guess on tomorrows action but if it follows the pattern then recovery to next level in the next couple of sessions is inevitable IMO.VERY serious manipulation on it but at least theses clowns are allowing a beautiful uptrend both short term and on the weekly charts.With the news of today I hardly think the trend will reverse.
IP: Logged |
posted
I protected, profited and left a little to gamble tomorrow. I am in a nice place right now with this stock. So, you don't bother me with what you are saying.
I know you (Purl) are smart enough to know what I meant and you know you took it to an extreme in your last post.
You're very bright and you know you don't need to pop in after it is all over and produce the proverbial slap in the face to those who made a mistake.
I really do not care to engage further on this.
Like I said I appreciate and respect your explainations.
-------------------- - "Pay it Forward"
IP: Logged |
posted
As a child growing up on our rural Oklahoma farm, a very harsh life, I learned early on every mother hen will, eventually, introduce her chicks to the fox, with apparent lack of tact and concern.
Surviving chicks of this introduction learn well, "The fox will eat me."
Again, this is a cut-throat business. When topics move around to discussion of a stock, there is no place for sundry pleasantries. When things come down to money, nobody is your friend.
"this is going to continue going down. you don't come off a multi day steroid run and not have at least a few down days in a row"
Precisely.
Trick on plays like this is to jump in and out, very quickly, as many times as possible. When you lose money, that is your last trade.
What truly happens, Weatherbill, people become greedy, fool themselves into thinking, "This will keep going up." Ain't so. Jump in, make a _modest_ profit and get the heck out.
If another profit chance appears, jump in and out again, and again, until you know any further trading will be a loser.
Darn it, people, take a five percent profit, take a ten percent profit, then walk away.
All kinds of warning signals popped up on this one over the past couple of weeks. Do not ignore those warning signals. Take your _modest_ profit and move on to the next play.
quote:Originally posted by Purl Gurl: As a child growing up on our rural Oklahoma farm, a very harsh life, I learned early on every mother hen will, eventually, introduce her chicks to the fox, with apparent lack of tact and concern.
Surviving chicks of this introduction learn well, "The fox will eat me."
Again, this is a cut-throat business. When topics move around to discussion of a stock, there is no place for sundry pleasantries. When things come down to money, nobody is your friend.
If The Donald was here, he would sternly say,
"You are all fired!"
Purl Gurl
I was in the right mind to tell you off until this post. I was rolling...and true.
IP: Logged |
posted
"No, today's news is old news and is not excellent.
The entire premise of his article is fatally flawed.
Use of fatally flawed logic is unavoidable for a pump and dump article; truth must be avoided."
All knowing Purl, please enlighten us on how this is "old news", as I recall there has never been approval from Nigeria gov't agency.
I bet you have read the prelim studies leading to approval or even better, application for approval
And I am sure you have researched Dr. Ramesh Pandey's work in sickle cell disease and treatment
Thanks for your input, but it is unfortunate you post with apparently little DD. Post all you wish but those who have actually spent the time to read the studies, pull Dr. Pandey's research history, worked with sickle cell patients, and are experts in medicine will understand the opportunity present.
IP: Logged |
quote:Originally posted by worthashot: My guess is that XKEM will be a gapper tomorrow. Today was panic sellers set off by MM manipulation. The MMs weren't expecting news since it didn't come out at it's usual 6:30 am and they didn't want the stock to run today because they hadn't collected enough shares.
Many people hadn't had a chance to even see the news of NAFDAC approval until after the bell. There will be so many buy orders tomorrow the MMs won't know what to do.
Worth, after reading all those crap that some "hard-core" teachers and others are trying to "teach" us newbs, I think your explanation makes the most sense.
I tend to agree with what you have posted here, and think a rebound may happen soon. I am on of the longtime holders of this stock, doing my DD thinking the AIDS work would come to pasture before this Sickle Cell drug did.
My plans are to hold it long/longer, and see no reason for everyone to panic. We are still higher than we were 4 months ago, in the .015 range
GLTA tomorrow, hopefully the flippers can do their work, and move to their next stock, so the "longer-termed" holders can hope for a better next few weeks,months,years.
posted
Portman you answered correctly, 2 stars for you...unfortunately in the pennies until the PR is as stated it is all just speculation, therefore if it were old news it would have been PR'd as approval previously
IP: Logged |
posted
"Thanks for your input, but it is unfortunate you post with apparently little DD. Post all you wish but those who have actually spent the time to read the studies, pull Dr. Pandey's research history, worked with sickle cell patients, and are experts in medicine will understand the opportunity present."
Oh, I am very well read on this company.
I will comment the good doctor forgot to add one item to his exceptionally long list of cures to be effected, "We are working on a cure for death."
posted
"We are working on a cure for death." You are correct on this, unfortunately it takes many small steps to reach that ultimate goal...hmmm sounds like a company I know
IP: Logged |
posted
"Just a quick question, do you even know what happens when you have an outbreak of sickle cell anemia?"
GAK! That one truly floors me!
I know there are a lot of people out there facing challenges in education. However, this is mondo beyondo, even for a pump and dump scamster!
Yes, the company lists too many "treatments," too many "cures," too many piles of mule manure.
Dang, people, the man is selling Snake Oil.
Wake up! You can buy the same products at your favorite shopping mall health food store.
Maybe not in Nigeria; people are in dire poverty which is so tragic, especially knowing people out to make money are using those unfortunate people as a basis for monetary profit.
posted
mnvestor, you seem to know a little something about pharmacuticals, maybe you could elaborate on what you have read. you probably even know the write spelling of the word?
posted
E440 - She came out of nowhere to make fun of people and treat them like they are beneath her. No need to keep encouraging her spiteful behavior. Just visit her web site and you will see the type of person she is. While I believe her to enjoy being trash, she knows her stuff when it comes to stocks. She doesn't care at all what anyone else thinks and believes it makes her cool to act like that. Please don't encourage her or she will find many ways to call you stupid. There are better people to talk to on here. Please stop wasting your time and ours by giving her ammunition to act like she is so much better than everyone. Sadly, I thinks she does care and would like people to learn, she's just ignorant when it comes to communication. She's brash, rude, arrogant, disrespectful and does not care.
IP: Logged |
posted
I am not under the impression that this "herbal drug"..is a cure...not at all...it is a way of managing the illness...treating the symptoms...lessoning the "effects of the SCD...
Correct me if I am wrong...I know you all will...LOL
By the way...I fully beleive that THIS IS POSSIBLE! We will see if it is here and now...but it is possible...
-------------------- #1 Rule: Protect your capital! #2 Rule: Never fall for the BS on the boards!
IP: Logged |
quote:Originally posted by cassity: 10of13 and amswap, did you guys kiss and make up. Too much tension on these threads!!
We were never at odds that I am aware of. I like 10 a lot. We've had a lot of fun on this thread and my pestering may have given some the idea that we didn't like each perhaps. No bad feelings here at all.
IP: Logged |
quote:Originally posted by cassity: 10of13 and amswap, did you guys kiss and make up. Too much tension on these threads!!
We were never at odds that I am aware of. I like 10 a lot. We've had a lot of fun on this thread and my pestering may have given some the idea that we didn't like each perhaps. No bad feelings here at all.
i hate you!
-------------------- #1 Rule: Protect your capital! #2 Rule: Never fall for the BS on the boards!
IP: Logged |
posted
Ten of Something is not afraid to comment nor ask,
"I am not under the impression that this "herbal drug"..is a cure...not at all...it is a way of managing the illness...treating the symptoms...lessoning the "effects of the SCD..."
You are perfectly correct.
There is no cure for a congenital disorder.
Best hope is to treat symptoms and side-effects.
After decades of intense study and research, advances in treatment are no farther along than fifty years back.
Some glimmer of hope through bone marrow transplant and stem cell therapy, but a lot of people die from those treatments.
Problem here is multifaceted. This herbal treatment does not treat anything more nor any better than current available treatments. Simple treatment really, thinning blood to help prevent clotting.
This can be effected with digitalis which is available through your backyard garden; foxglove.
Foxglove is also a great way to murder someone; leaves no traces behind for an autopsy; apparent heart attack is cause of death.
Another problem here is a subsidairy of this company is nothing more than a herb store, a health food supplier. Those are a dime a dozen as you know.
Adding to this news hypes treatments for all kinds of ailments, from cancer to HIV. Readers well know that is mule manure.
posted
In the studies (both human and animal), it was shown to reduce "sickling" of hemoglobin S, with reduction in sickling, patients experience fewer episodes of pain related to abnomal passage through vessels, aka crises...Remember even though sickle cell disease is an congenital/inherited disease, patients also produce normal hemoglobin A (which can effectively carry oxygen and pass through the smallest of vessels. With Nicosan, it appears there is a significant reduction in pain and occurence of the crisis state, possible related to the reduced amount of sickling. So no it does not appear to be a cure, just a novel therapeutic option..
IP: Logged |
Xechem International, Inc. ("Xechem" or the "Company") is a public holding Company. Xechem Inc., a subsidiary of Xechem International, Inc. is engaged primarily in applying its proprietary extraction, isolation and purification technology to the production and manufacture of paclitaxel (commonly referred to in the scientific literature as "Taxol®," a registered trademark of Bristol-Myers Squibb Company ("Bristol Myers")). Paclitaxel is an anticancer compound used for the treatment of ovarian, breast, small cell lung cancers and AIDS related Kaposi sarcomas. The Company has successfully isolated pure paclitaxel and has received a process patent on this technology. The Company has submitted to the FDA a Drug Master File ("DMF") for the facility and the bulk paclitaxel product. The Company has been issued five U.S. patents on paclitaxel and its second generation analogs from the U.S. Patent and Trademark Office and over thirty-four international patents are pending.
In addition to the Company's focus on the development and production of paclitaxel, the Company has continued to apply its expertise to research and develop other niche generic compounds, by microbial fermentation or semi-synthesis and on the development of drugs from sources derived from Chinese, Indian and other traditional medicinal plants in the anticancer, anti-fungal, antiviral (including anti-AIDS), anti-inflammatory, anti-aging and memory enhancing areas. Some of these efforts are performed in collaboration with the National Cancer Institute ("NCI") and the National Institutes of Mental Health (''NIMH'').
The Company has a subsidiary, Xechem (India) Pvt., Ltd., in New Delhi, India.
The Company has also established a subsidiary, XetaPharm, Inc. ("XetaPharm"), to develop and market over-the-counter natural product health supplements "NUTRACEUTICALS" such as GinkgoOnce®, GarlicOnce®, GinsengOnce®, GugulonTM, and CoEnzyme Q-10.
Traditional plant medicines have been valued in various cultures throughout the ages for their therapeutic and healing properties. In recent decades, modern investigations have led to the systematic screening of thousands of plants and other natural products for a variety of biological activities. Several commercially successful pharmaceuticals based upon these medicines have exhibited activities useful in treating cancer, fungal and viral infections (including AIDS), and in retarding aging and senescence. Ethical pharmaceuticals currently in use having plant origins include: L-dopa, used for the treatment of Parkinson's disease; pilocarpine, used to treat glaucoma; quinine, used to fight malaria; and vinblastine and vincristine, used to treat certain cancers, both of which come from India and the People's Republic of China. In addition, drugs such as aspirin, ephedrine, digitalis, paclitaxel and camptothecin originated from plants-found in temperate regions of the world. Valuable natural-product pharmaceuticals may be derived from a variety of medicinal plants, marine sources and fermentation processes.
Xechem People
Dr. Ramesh Pandey (Founder, Chairman and CEO)
Ramesh C. Pandey, M.Sc., Ph.D., D.D.G, FAIC, Chairman, Chief Executive Officer and founder of Xechem, Inc., XetaPharm, Inc., Xechem (India) Pvt. Ltd, Xechem Pharmaceutical China Ltd., Xechem Pharmaceuticals Nigeria Ltd., Xechem UK, Ltd. and Chairman of the Board and CEO of Xechem International, Inc., a publicly held US Company, has had a distinguished career in the biomedical sciences spanning over 40 years. He has served numerous universities, government agencies and pharmaceutical companies worldwide, including: The National Cancer Institute; LyphoMed, Inc.; The University of Illinois; Rutgers, The State University of New Jersey; National Chemical Laboratory (NCL); Abbott Laboratories; and others.
Experienced in coordinating projects between universities and industries to develop drugs of commercial importance, Dr. Pandey has provided innovative solutions to various problems in the isolation, purification, process development, and commercial scale production of biologically active pure compounds from natural sources using the most advance state-of-art technologies and bio-technologies. For the past ten years, he has been involved in the research, development, novel extraction/purification processes and production of proprietary and generic drugs from Worldwide indigenous natural sources, especially the Traditional Chinese Medicines (TCM), Ayurvedic Indian Medicinal Plants and recently the Nigerian Medicinal Herbs used in the folklore for various ailments.
Under Dr. Pandey’s direction Xechem successfully developed its first product, Vancomycin (an antibiotic produced by fermentation). He has been responsible in leading Xechem’s group to develop a commercial process for paclitaxel bulk material from Taxus plant (yew) extracts under current Good Manufacturing Practices (cGMP). He also led Xechem to develop nine new, next-generation paclitaxel analogs with better anticancer activity. Dr. Pandey has been the Principal Investigator (PI) on several Small Business Innovative Research (SBIR) Grants for National Cancer Institute (NCI), National Heart, Lung and Blood Institute and National Aeronautics Space Administration (NASA). Also, under his leadership, XetaPharm has brought to the market a line of standardized nutraceutical products, including GinsengOnce®, GarlicOnce®, GinkgoOnce®, Gugulon™, Co-Enzyme Q-10 and VIDAPRAS™ (an Ayurvedic product used in India for hundreds of years for rejuvenation).
Dr. Pandey is presently guiding Xechem in developing a phyto-pharmaceutical, HEMOXIN™/NICOSAN™ (NIPRISAN), for the treatment of Sickle Cell Disease (SCD). Xechem has worldwide license to this product from the National Institute for Pharmaceutical Research and Development (NIPRD), Government of Nigeria, Abuja, Nigeria. The United States Food and Drug Administration (US-FDA) and the European Evaluation Agency (EMEA) for European Union (EU) have designated this product an Orphan Drug status. Dr. Pandey plans to take it through an Investigational New Drug (IND) application as a prescription phyto-pharmaceutical with the FDA.
Dr. Pandey has made over one hundred presentations at National and International conferences and seminars, has authored (or co-authored) 95 peer reviewed scientific papers and contributed to several books treating chemistry or biochemistry topics of major importance. He also holds several U.S. and International patents for biotechnology analysis and rare drug production processes, including paclitaxel, a plant product used for the treatment of ovarian, breast, small cell lung cancers, AIDS related Kaposi's sarcoma and stomach cancer.
In his career spanning over 40 years, Dr. Pandey has been associated and listed in: Who’s Who in Technology Today, Vol. 3 Chemistry and Biochemistry, 4th Edition, 1984; Who’s Who in the Midwest, 19th Edition, 1984 – 1985; American Men and Women of Science, 16th Edition, 1986; Who’s Who in U.S. Executives for 1989; Who’s Who in America Science and Engineering, 1st Edition, 1992/1993; Member of Board of Advisors, International Who’s Who of Professionals, 1996 – Present; Appointed "Deputy Director General" (DDG) of the International Biographical Centre for Americas, International Biographical Centre, Cambridge, England, March 16, 2000; Gold Star Award for contributions to Scientific Research in the following titles – “2000 Outstanding Scientists of the 20th Century” by the International Biographical Center, Cambridge, England, 18th September 2000; Who’s Who Worldwide Business Leaders 1994/95; Esteemed Member of Sterling Who’s Who Executive Edition; Who’s Who Historical Society, 2001 Edition of International Who’s Who of Professionals; Lifetime Member - Lexington Who’s Who Registry of Executives and Professionals, 2001-2002 Edition.
Dr. Pandey is a member of the editorial board of the Journal of Antibiotics and of several professional societies including the American Chemical Society, American Association for Cancer Research, American Society of Pharmacognosy, American Society of Microbiology, Industrial Microbiology, Indian Science Congress and New York Academy of Sciences. He is one of the founding members (founded in 1999) and Executive Trustee of the American Academy of Ayurvedic Medicine, Inc. (AAAM®). He has recently (2001) founded and registered G. D. Pandey Ayurved University (GDPAU) at New Brunswick Technology Center, NJ, USA for the education and research on Ayurveda (Science of Life).
For his on going work in bringing quality control, standardization and setting specifications in Ayurvedic preparation, Dr. Pandey was honored “Vaidya Ratna” at the Fourth International Healthcare & Herbal Expo and Seminar, New Delhi, India, April 2004.
Dr. Ramesh Pandey hails from Ranikhet (District Almora, Uttaranchal), located in the foothills of the Himalayas in North India. He has generations of association with Ayurveda since his father was the personal physician of the royal family of Kumaon. Dr. Pandey had his initial schooling in Kumaon and thereafter did his Ph.D. from the National Chemical Laboratory (NCL)/Pune University, Pune, INDIA.
COMMUNITY SERVICE Dr. Pandey is also a member on the Statewide Advisory Committee of the Board of Managers, New Jersey Agricultural Experiment Station, Rutgers, The State University of New Jersey, in the field of Biotechnology for the term 2002 – June 30, 2008.
New Jersey Technology Council (NJTC) Life Sciences Advisory board Member.
He was a member of the Advisory Committee for the Science Transfer and Science Technology Program at Middlesex County College, Edison, New Jersey: (1999-2001).
Middlesex County, New Jersey Work Force Investment Board Member (1999 - May 2005).
Member and Paul Harris Fellow of the New Brunswick Rotary Club (1996- ) and President for the term 1999-2000. He has been instrumental in helping children and down trodden in South Africa, Nigeria and India.
Dr. Renuka Misra (Director, Natural Products)
Dr. Renuka Misra is the Director of Natural Products and Xechem Scientific Advisory Board member. She has studied the Chemistry of Bioactive Natural Products for over twenty years. Her current research interests are in the areas of Alternative Medicines, including Screening of Natural Products, specifically Ayurvedic (Indian System of Medicines) and Chinese Traditional Medicinal Plants for modern drug development, using current analytical methods.
Dr. Misra's expertise is in the isolation, purification, and X-ray crystallographic structure determination of Natural Products. She has published over 80 scientific articles in peer-reviewed Journals, and authored four definitive books on diterpenoids, published by CRC Press, Boca Raton, Florida.
Dr. Misra has worked at a number of research centers including the University of Nebraska, North Carolina State University, the University of Toronto, the University of Illinois, John Hopkins University and the NCI-Frederick Cancer Research Facility. Dr. Misra received her Ph.D. from the National Chemical Laboratory, Poona, India in 1965.
Dr. Renuka Misra is a member of several Scientific Societies and recipient of many awards and honors including the Sir C.V. Raman Science Research Award in the field of cancer research in 1988 and UNDP/TOKTEN Scientific Collaboration Program between the USA and India in 1992.
She has a guest research scientist appointment with the National Institute on Aging (NIA), National Institutes of Health (NIH).
Sickle Cell Research, Efficacy, Awareness and Marketing Advisory Board
The Company established the Sickle Cell Research, Efficacy, Awareness and Marketing Advisory Board (the "Sickle Cell Advisory Board"), which consists of distinguished individuals from the fields of pharmaceutical sales and marketing, urban marketing, international consulting, professional networking, entertainment, academia and business to assist the Company’s management in creating public awareness of its efforts to bring an effective treatment for Sickle Cell Disease to market in the United States and globally. The following are the current members of the Sickle Cell Advisory Board:
Vincent A. Carter , MBA Desiree V. Delgado George C. Fraser, Ph.D. Glenda Baskin Glover, Ph.D., CPA, JD Marcellus Grace, Ph.D.. Nadine B. Hack, MPA, MALS J. Wayman Henry III Wallye Inese Holloway Stephen H. Kolison, Jr., Ph.D. Kofi Lomotey, Ph.D. Tamara New, M.D. Dakota Pippins, MBA Marcy Street, M.D.
Vincent A. Carter, MBA is an experienced pharmaceutical industry professional who has distinguished himself as an effective, results-oriented business executive within the healthcare industry over the last nineteen (19) years. Mr. Carter’s breathe of experience touches on virtually every component of the healthcare industry: manufacturing, distribution, contracting/reimbursements and insurance. Mr. Carter has worked for such leading pharmaceutical companies as Lederle Laboratories (currently American Home Products), Miles, Inc. (currently Bayer AG), Fujisawa USA where his charge was to promote both branded and generic pharmaceutical products to office-based physicians, community hospitals, teaching/university hospitals, specialty pharmacy distribution companies, industry wholesalers and retail pharmacies. Mr. Carter has also served as a Business Director for Connetics Corporation, a start-up, Palo Alto, California based biotechnology company, where he was responsible for development of the company’s trade/distribution policy as well as responsibilities for successful launching of a new dermatologic product to the trade community (industry wholesalers and chain/retail pharmacies). In 1999, Mr. Carter started 4th & Short Distribution, Inc., a pharmaceutical wholesale and medical supplies distribution company located in Brooklyn, New York that focused on urban markets and healthcare professionals. He then became Regional Marketing Manager for Fidelis Care New York, a Managed Medicaid company, where some of Mr. Carter’s duties included restructuring an eighty-four (84) person sales force. In 2004, Mr. Carter joined MedImmune, Inc., which manufacturers a monoclonal antibody used in premature babies to prevent a very serious virus and a revolutionary influenza vaccine. Mr. Carter is responsible for developing a team of sales people and Clinical Marketing Managers to promote MedImmune’s products to the Pediatrician community and major teaching/university hospitals. Mr. Carter is an active member of the Healthcare Committee for One Hundred Black Men of New York. Mr. Carter received his Master of Business Administration degree in Pharmaceutical Marketing in August 1995 from St. Joseph’s University in Philadelphia, PA.
Back to Sickle Cell Advisory Board
Desiree V. Delgado is President and Chief Executive Officer of R2Network.net, Ltd. A DelzBrük Company, a general market media company offering a full-range of services to support the advertising, marketing and public relations process. Mrs. Delgado is a highly skilled marketing professional with over fifteen (15) years of experience in key marketing positions. She has worked in marketing capacities for Gospel radio stations and has assisted with promoting numerous entertainment events consisting of Comedy, Gospel, Gospel Stage Plays, R&B, Hip Hop, and Jazz. As a Board Member of “Golden Heart,” a non-profit organization that gives aid in helping under-privileged youths in the inner cities, she volunteers in promoting an annual aviation “Air Show” event that attracts over 3,000 youths. Mrs. Delgado believes in healing through music to promote the awareness of Sickle Cell Disease, as she has a family member that suffers from the disease. Mrs. Delgado studied Business Administration at the University of Akron in Ohio and continued her education at the Mannheim Institution in Germany.
Back to Sickle Cell Advisory Board
George C. Fraser, Ph.D. is chairman and CEO of FraserNet, Inc., headquartered in Cleveland, Ohio, which is the publisher of the award-winning SuccessGuide Worldwide; The Networking Guide to Black Resources, which is published annually. His vision is to create a global networking movement that brings together diverse human resources to increase opportunities for people of African descent. He actualizes this philosophy by producing tools, products and services that teach and promote effective networking as a way to strengthen individuals and communities to promote America’s business agenda. Dr. Fraser is the author of two books, the critically acclaimed best sellers Success Runs In Our Race: The Complete Guide to Effective Networking in the African American Community and Race for Success: The Ten Best Business Opportunities for Blacks in America. Success Runs in Our Race is one of the few written by an African-American, to be selected to celebrate its 10th Anniversary with an updated reprinting. The prestigious Booklist Magazine selected Race for Success as one of the ten best business books of the year. Over the past decade the prestigious publication Vital Speeches of the Day has selected five of his speeches to be reprinted and distributed worldwide, a first for any professional speaker in America. Black Enterprise Magazine called him “Black America’s networking guru” and has featured him on its cover. Upscale Magazine named him one of the top 50 power brokers in Black America. FraserNet, Inc. hosts the annual PowerNetworking Conference in Cleveland, Ohio, America’s largest networking event for African Americans. He has appeared on more than 250 television and radio talk shows, and speaks nearly 120 times per year around the world. His inspiring talks on success principles, effective networking, wealth creation, ethics, and the importance of diversity are as popular with professionals, as they are with college students. Dr. Fraser spent 17 years in management with Procter & Gamble, United Way, and Ford Motor Company. He received his executive training at the Tuck School of Business at Dartmouth College and was awarded an Honorary Doctorate Degree of Humane Letters from Jarvis Christian College.
Back to Sickle Cell Advisory Board
Glenda Baskin Glover, Ph.D., CPA, JD is the Dean of the School of Business at Jackson State University in Jackson, Mississippi. She is a Certified Public Accountant, an attorney and a higher education administrator. She holds a Ph.D. in economics and finance, and is one of two African American women to hold the economics Ph.D-CPA-JD combination in the nation. Her corporate and other national board memberships include: Board of Directors of Citibank Student Loan Corporation, Union Planters Bank of Jackson, Harvard Business School Management Alliance and the American Assembly of Collegiate Schools of Business (AACSB). She is a board member of the Metro Jackson Chamber of Commerce and NAACP. She is also Chairperson of the Board of Commissioners for the Jackson Municipal Airport Authority in Jackson, MS. Other affiliations include the Minority Capital Loan Fund, AICPA, National Bar Association, and Alpha Kappa Alpha Sorority, Inc.
Back to Sickle Cell Advisory Board
Marcellus Grace, Ph.D. has served as Professor of Pharmacy Administration and as the Associate Dean of the School of Pharmacy in the College of Pharmacy, Nursing and Allied Health Sciences at Howard University in Washington, DC since July 2004. He has also served as Dean and Professor of Pharmacy Administration in the College of Pharmacy at Xavier University of Louisiana in New Orleans, LA, where he was affiliated with the College of Pharmacy in different capacities between 1983 and 1999. Prior to joining the faculty of Xavier University, he was on the faculty and served in different capacities at Howard University between 1979 and 1982, including Chairman - Department of Pharmacy Administration, Interim Chairman – Department of Pharmacy Practice and Assistant Dean for Service Education. Dr. Grace is licensed as a Registered Pharmacist in five states. He has also served as a Commissioned Officer in the U.S. Naval Reserve, retiring with the rank of Captain – Medical Service Corps. Dr. Grace has received numerous awards and honors, including being mentioned in numerous “Who’s Who” publications. He has held board member, officer and other leadership positions in numerous professional associations, non-profit organizations and academia, and currently holds memberships in several organizations. He has been instrumental in securing a number of research grants and his writings have been widely published and cited. He has also lectured extensively around the country on various pharmaceutical and health related topics, often speaking on topics relating to diseases and pharmacy issues that affect the African American community. Dr. Grace received his M.S. in Hospital Pharmacy and Ph.D. in Pharmacy Administration from University of Minnesota and his B.S. in Pharmacy from Xavier University of Louisiana.
Back to Sickle Cell Advisory Board
Nadine B. Hack, MPA, MALS is the Founder and President of beCause Global Consulting, Inc. (“beCause”), which offers its clients over 25 years of experience in strategic planning, project implementation, creative problem solving, policy analysis, fundraising and politically sensitive negotiations. beCause is a global consulting firm that conceives, develops, facilitates and executes the cause-related strategies and initiatives of corporate and nonprofit clients to build awareness of and support for humanitarian efforts. Ms. Hack has provided guidance to or created strategic partnerships for clients internationally and has produced hundreds of their special events, campaigns, projects and unique events globally. Her vision is at the helm of every beCause operation, providing clients with a wealth of knowledge and experience. Ms. Hack has extensive experience with the United Nations, where she served as New York City Commissioner for the United Nations, Consular Corps and International Business, the city’s senior official liaison with the world’s largest diplomatic and business communities. She has served as an advisor to the UN Secretary-General, various departments of the UN Secretariat and many specialized UN agencies. Ms. Hack has also served as an advisor to government officials, including President Corazon Aquino of the Philippines; the African National Congress executive committee in exile in Lusaka, Zambia; and, subsequently, the government of South Africa’s President Nelson Mandela. She was president of the Sister City Program of the City of New York where she managed financial, technical, educational, sports and cultural exchanges with cities globally. In the course of her diverse career, Ms. Hack has led multi-million dollar fundraising efforts for organizations, causes and campaigns. She often links private resources with public needs in order to promote the advancement of women, children, minorities, human rights, civil liberties, health, the environment and economic development. Her activities have taken her around the world as a member of official delegations and fact-finding missions.
The Boards on which she currently serves include the Desmond Tutu Peace Foundation (President), Africa-America Institute (Vice Chair), World Policy Institute, International League for Human Rights, and Synergos Institute. Advisory councils on which she currently serves include Amnesty International USA, United Nations Association of New York, Human Rights Watch - Africa Division and NAACP Centennial Advisory Task Force. She has served on more than two dozen boards or advisory committees including the Martin Luther King Jr. Center for Nonviolent Social Change, Women’s Commission for Refugee Women and Children, NAACP, Ms. Foundation for Women, New York State International Partnership Program and the Democracy Project. Ms. Hack’s awards include New York Women’s Agenda Star, International Outstanding Achievement, New American Leader, Woman of the Year, Distinguished Women of New York, SAAO Leadership, AJC Louise Waterman Wise and Madame C. J. Walker Awards. She has Master Degrees from the John F. Kennedy School of Government at Harvard University (MPA) and the Graduate Faculty of Political and Social Science at New School University (MALS). She is adjunct professor of a course she created for the International Program at the Wagner Graduate School of Public Service at New York University, Development Strategies & Initiatives for Global Nonprofits: Internal & External Capacity-Building; Understanding, Creating & Sustaining Effective Multi-Sector Partnerships. Back to Sickle Cell Advisory Board
J. Wayman Henry III has over ten (10) years of experience in financial analysis, contract negotiations and marketing. He is Co-Founder and Vice President of Business Development of E-Merge International in Atlanta, GA, where he oversees all of the firm’s business operations in sports marketing, entertainment representation, National Football League apparel, event planning and intellectual property development. Mr. Henry previously owned JW Entertainment Group, where he was directly responsible for managing promotional activities, generating corporate and consumer sales, and developing intellectual properties and events for major fortune 500 companies and the National Football League until it was acquired by E-Merge International in 2003. Prior to forming JW Entertainment, Mr. Henry was co-founder and Vice President of Sports and Entertainment International, Inc., a sports and entertainment marketing firm. Mr. Henry also previously worked under the State of Maryland’s former State Treasurer, Mr. Richard N. Dixon, where he served as Assistant to the Treasurer and Director of Securities with key responsibilities including oversight of the $1 billion dollar investment portfolio for the State of Maryland and oversight of municipalities’ financial and securities practices, including the City of Baltimore. Mr. Henry provides financial and other support to several charitable organizations, including the Sean Carter Scholarship Fund, NFL YET Center, Ahanotu Foundation and Boys and Girls Club of America, and has served on the Board of Directors of the Eric Davis Foundation. He actively participates in a mentoring program with the JAIMAN Foundation (which stands for Join Athletes In Mentoring Adolescents Nationwide). A former athlete himself, Mr. Henry leverages his close working relationships with professional athletes to foster economic development. Mr. Henry has received honors including Who’s Who Among Students in American Universities & Colleges, Full Bright Scholar Candidate, Disney’s Economic and Entrepreneurship Conference Award, Congressman Reynolds / President Bush Business Advisory Committee Honorary Chairman and being listed as one of the most successful young professionals by Who’s Who in America. Mr. Henry obtained an undergraduate degree in Business Administration and MBA in Finance from the Earl G. Graves School of Business and Management at Morgan State University. He also attended law school at the University of Chicago School of Law.
Back to Sickle Cell Advisory Board
Wallye Inese Holloway is a Vice President and Account Group Supervisor of Cline Davis & Mann, a leading and award winning pharmaceutical marketing, brand development and advertising agency in New York City, where she has managed the marketing and brand development strategies for large pharmaceutical companies, including Pfizer and Amgen since June 2002. Prior to joining Cline, Davis & Mann, Ms. Holloway worked in similar leadership capacities over a period of seven years in New York City with several pharmaceutical marketing and brand management firms, including KPR, Sandler Science, Lowe McAdams Healthcare, and FCB Healthcare. Prior to taking on managerial responsibilities, Ms. Holloway honed here pharmaceutical sales and marketing skills over six years as an Account Executive and Marketing Representative for Lederle Laboratories, in Denver, CO and Wayne, NJ and Allergan Optical in Denver, CO. Ms. Holloway has managed or assisted with brand marketing strategies and campaigns for drugs manufactured by major pharmaceutical companies, including Merck, Boehringer-Ingelheim, Roxane Laboratories, Roche, Schering-Plough, Aventis Pasteur and Aventis Pharmaceuticals. She has worked with drugs treating diseases in several therapeutic categories, including HIV therapy, oncology, generics, cardiovasculars, antibiotics, nicotine transdermal therapy, biologicals, nutritional supplements, anti-infectives, and pediatric vaccines. Ms. Holloway’s experience includes strategic and tactical market planning and implementation, brand positioning, promotional messaging, creative imagery, and medical professional education. Ms. Holloway obtained her B.S. in Marketing from Jackson State University in Jackson, MS.
Back to Sickle Cell Advisory Board
Stephen H. Kolison, Jr., Ph.D. is the Dean and Research Director of the Institute of Agricultural and Environmental Research at Tennessee State University in Nashville, TN. Dr. Kolison, Jr. assumed the leadership of the Cooperative Agricultural Research Program (“CARP”) at Tennessee State University in August 1998 as Research Director, and CARP was elevated from a research program to the Institute of Agricultural and Environmental Research in August 2003. Dr. Kolison, Jr. has overall administrative responsibility for agricultural and environmental research at Tennessee State University. Prior to joining Tennessee State University, Dr. Kolison, Jr. was Professor of Forestry/Forest Economics and Coordinator of the Forest Resources Program at Tuskegee University. Under his leadership, Tuskegee University conferred its first Bachelor of Science degrees in Forestry. Dr. Kolison, Jr. is a recipient of several awards and recognitions, including include the “Faculty Advocate Award for Superlative Leadership in Program Development” from Tennessee State University in 2003, the “Faculty Achievement Award” from Tuskegee University (Tuskegee University’s highest academic award) in 1997, and the first “B.D. Mayberry Young Scientist Award” from the Association of Research Directors, Inc. in 1994. He has served on many national and regional committees including the Society of American Foresters Committee on Accreditation. His research expertise is in the area of economic impact assessment of forest policy and management. His international experiences include research conducted in the Republic of Trinidad and Tobago, Jamaica, and Ghana, and other professional activities carried out in Belgium, Brazil, Finland, and The Netherlands. He has published scientific papers widely and spoken to numerous audiences throughout the United States. Dr. Kolison, Jr. obtained his Ph.D. and M.S. degrees in Forest Economics from Iowa State University of Science and Technology and his B.Sc. degree in General Forestry in 1983 from the University of Liberia. He has received formal and intensive training in “Public Policy and Executive Leadership in Higher Education” from the Fischler School of Education and Human Services of Nova Southeastern University, “Challenges in Risk Communications” from the Harvard University School of Public Health, and “Global Trade Analysis” from the Institute of Agricultural Economics in The Hague, The Netherlands. In November 2002, Dr. Kolison was elected Chair Elect of the Association of Research Directors, Inc. and in November 2004, he assumed the role of Chair and Chief Executive Officer of the Association of Research Directors, Inc.
Back to Sickle Cell Advisory Board
Kofi Lomotey, Ph.D. is a Senior Fellow at the American Association of State Colleges and Universities. He is the former President of Fort Valley State University in Fort Valley, GA. He was previously at Medgar Evers College of The City University of New York, where he was the Senior Vice President and Provost. Earlier, he was in the College of Education at Louisiana State University in Baton Rouge, LA where he served on the faculty and in the Department of Education Administration and Foundations as the University’s first African American Chair. Prior to the LSU appointment, Dr. Lomotey was on the faculty in the Graduate School of Education at the State University of New York at Buffalo. Dr. Lomotey is the editor, co-editor or author of seven books and has published numerous articles and book chapters. He is the editor of the journal, Urban Education, and is the Secretary/Treasurer of the Council of Independent Black Institutions (“CIBI”), an umbrella organization for independent African-centered schools. Dr. Lomotey holds a B.A. degree from Oberlin College in Economics, a M.Ed. degree from Cleveland State University in Elementary Curriculum, and obtained his M.A. and Ph.D. degrees from Stanford University in Elementary & Secondary Educational Administration and Policy Analysis. He has traveled extensively in Europe, Asia and Africa and regularly leads educational and cultural tours to West Africa.
Back to Sickle Cell Advisory Board
Tamara New, M.D. is the Director of the Comprehensive Sickle Cell Center at Harlem Hospital Center in New York, NY. Dr. New also holds other leadership positions at Harlem Hospital Center, including Director of the Pediatric Residency Program, Director of the Pediatric Hematology-Oncology of Harlem Hospital Center and Clinical Director of the third year medical student Pediatric Clerkship program. She has been an Assistant Professor of Pediatrics in the Department of Pediatric Oncology at Children’s Hospital of New York, Presbyterian Hospital, Columbia University since 2002. Dr. New did her residency in Pediatrics at UMDNJ – Robert Wood Johnson University Hospital in New Brunswick, NJ, one of the five hospitals that have committed to participating in Xechem’s FDA clinical trials. She belongs to several professional organizations, including American Society of Pediatric Hematology-Oncology, Sickle Cell Advisory Committee and American Society of Hematology. She has lectured on Sickle Cell Anemia at Harlem Hospital Center and Abyssinian Baptist Church. Dr. New was recognized at the press conference held by United States Senator Charles Schumer at Harlem Hospital Center in October 2003 to announce his support of the Sickle Cell Treatment Act of 2003 (passed into law in 2004), during which the rising rates of Sickle Cell Disease in central Harlem were discussed. Dr. New obtained her Doctor of Medicine degree from Mount Sinai School of Medicine, New York, NY and her BA in Chemistry from Smith College, Northampton, MA.
Back to Sickle Cell Advisory Board
Dakota Pippins, MBA is the Founder and CEO of Pippins Strategies, LLC, a marketing consulting firm that advises large corporations on strategies for attracting Urban consumers. Mr. Pippins established Pippins Strategies, LLC in 2003 after leaving Vigilante/Publicis Inc., where he founded and served as Director of The Urban Think Tank (the company’s strategic planning and research unit). Since January 2001, Mr. Pippins has served on the Board of Directors of Hormel Foods Corporation and places emphasis on corporate governance. His previous experiences include serving as Director of The Management Institute of New York University (“NYU”), Senior Vice President-Planning and Development for the T&E Services (credit cards) division of Citicorp, Senior Vice President at the Chisholm-Mingo Group advertising agency, Co-Founder-CEO of UTO Direct, Vice President-Management Supervisor at Burrell Communications Group advertising agency, and various marketing management positions at General Foods, where he began his marketing career. Mr. Pippins has successfully developed and managed businesses in package goods, financial services, telecommunications and durable goods. While at General Foods, Mr. Pippins developed Crystal Light, one of their most successful products of the last 20 years. As a Senior Vice President of a division on Citicorp, he managed the development of an award-winning marketing program that resulted in a dramatic increase in the company’s market share among business travelers. Mr. Pippins is an Adjunct Assistant Professor at NYU where he served for five years as Director of NYU’s Management Institute and currently teaches a course on Urban Marketing Strategies. Also, while at NYU, Mr. Pippins developed the university’s first course in Integrated Marketing Communications and served as Director of the Center of Direct Marketing. Mr. Pippins has lectured extensively on marketing strategies at numerous institutions, including. Northwestern University’s Kellogg Business School, NYU’s Interactive Marketing Institute and the Direct Marketing Association. During 1995 and 1996, he traveled extensively throughout West Africa and co-founded Sustainable Community Development Network, Inc. (“SCDN”) an organization dedicated to building sustainable communities in both the United States and Africa. Mr. Pippins obtained his Masters of Business Administration degree from the University of Wisconsin and B.S. in Psychology from the University of Illinois, with a minor in Mathematics and Anthropology. Mr. Pippins also has an extensive background in Chemical Engineering.
Back to Sickle Cell Advisory Board
Marcy Street, M.D. is the owner of Doctor’s Approach Dermatology & Laser Center in Lansing, MI, and is a Member of the Michigan Board of Medicine & Disciplinary Committee. Dr. Street has been in private practice since 1991 as a Medical Dermatologist, Skin Cancer Specialist and Mohs Surgeon with a CLIA approved Mohs surgery laboratory. She is also a Cosmetic Dermatologist specializing in facial peels, Laser treatments, Botox™, collagen, spider veins and Thermage™. Dr. Street received the Entrepreneurial Award of Greater Lansing 2004 in the area of healthcare as the owner and residing physician of Doctor’s Approach Dermatology & Laser Center and for the development of her own product line, Doctor’s Approach Skin & Hair Care. Dr. Street holds memberships in several professional associations and business development agencies, including the American Society for Dermatologic Surgery, American Academy of Dermatology, and Minority Business Development Agency. Dr. Street is also a Clinical Instructor in Michigan State University’s Department of Internal Medicine, where she has lectured to medical students and residents on topics in general and surgical dermatology since 1991. She has written or contributed to at least 14 published articles relating to her field and research interests, and has lectured widely on various topics, including dermatology, skin cancer, laser surgery and Mohs surgery. Dr. Street has also been interviewed in several television and radio news segments on various topics within her field. Dr. Street received her M.D. from the University of Illinois College of Medicine in Chicago, IL and BA in Psychology from Oberlin College in Oberlin, OH. She has also performed graduate training at the University of Wisconsin (Madison, WI), Mayo Clinic (Rochester, MN) and Saint Joseph Hospital (Chicago, IL). She has received several certifications and has medical licenses in Illinois and Michigan.
Back to Sickle Cell Advisory Board
Scientific Advisory Board
The Company established the Scientific Advisory Board ("SAB"), which consists of scientists, researchers, and clinicians with recognized expertise in the Company's areas of research, to review the Company's research programs, advise with respect to technical or clinical matters, and recommend personnel. The following are the members of the SAB:
Elias J. Anaissie, M.D. Nitya Anand Ph.D., F.N.A. Prof. Federico Arcamone Brian Arenare, M.D. Joan W. Bennett, Ph.D. William T. Bradner, Ph.D. Geoffrey A. Cordell, Ph.D. Sukh Dev, Ph.D., D.Sc., F.N.A. Sun Han-Dong, Ph.D. Allen I. Laskin, Ph.D. Zhang Li-He, Ph.D. Renuka Misra, Ph.D. Lester A. Mitscher, Ph.D. Otto J. Plescia, Ph.D. C. L. Propst, Ph.D.
Elias J. Anaissie, M.D., is a Professor of Medicine, Director of Clinical Affairs of the Myeloma and Transplantation Research Center and the University of Arkansas School of Medical Sciences, Little Rock, Arkansas. Before joining the University of Arkansas, Dr. Anaissie was an Associate Internist and Associate Professor of Medicine in the Section of Infectious Diseases, Department of Medical Specialties, at the University of Texas System Center M.D. Anderson Hospital and Tumor Institute, Houston, Texas.
Back to Scientific Advisory Board
Nitya Anand Ph.D., F.N.A., is a Scientist Emeritus at the Central Drug Research Institute in Lucknow, India, of which he was the Director between 1974 and 1984. He was previously the Senior Scientist of the Indian National Science Academy. Dr. Anand has been involved in medicinal science research for over 40 years, during which he has worked in the areas of drug design, drug synthesis, mode of action, and metabolism of drugs, and in evolving new approaches to therapeutics. He was responsible for the discovery of many new drugs, which include Centchroman, a contraceptive, Centbutindole, a neuroleptic, Centbucridine, a local anaesthetic and Gugulipid, a lipid-lowering agent. Dr. Anand received his Ph.D. from Bombay University in 1948 and from Cambridge University in 1980.
Back to Scientific Advisory Board
Prof. Federico Arcamone, a University of Pisa, Italy, chemistry graduate and a student of the "Scuola Normale Superiore di Pisa" received a "Diplome d'etudes superieures de sciences physiques de l'Université de Paris (1952) and a "Libera Docenza" in biological chemistry in Rome (1962). As a research chemist at Farmitalia, Milan, he has been active in the field of natural products and antibiotic research, drug metabolism and organic synthesis, becoming Head of Chemical R&D in 1973. In 1987 was Chairman of the Research Division of the Menarini Company (Florence, Italy). From 1997 he is associated with the National Research Council also performing professional activity as a Consultant. His main achievements include the discovery and development of the antitumor anthracyclines doxorubicin, epirubicin, idarubicin and their analogs presently undergoing clinical evaluation, the structure elucidation and synthesis of new antibiotics, the development of new ergoline drugs and the synthesis of glycopeptides, penem derivatives and DNA conjugates.
Prof. Arcamone is author an co-author of over 200 research papers and reviews, over 100 patents and has been an active lecturer in different countries, especially in the US. He has been associated as a "contract professor" with the Universities of Bologna, Parma and Milan. He has received the Bristol-Myers award for Cancer Chemotherapy, (1981), the Gold Medal of the "Accademia delle Scienze detta dei XL" (1982), the Bruce Cain award of the American Ass. of Cancer Res. (1985), the Medal of the University of Florence (1992), the Gold Medal of the Italian Federation of Chemical Industries (1994), the Medal of the Italian Chemical Society, Carbohydrate Division (2000), and other scientific recognition. Prof. Arcamone is a member "emeritus" of the American Chemical Society, a member of the Italian Chemical Soc. of the Am. Ass. of Cancer Research, of the Am. Soc. of Pharmacognosy, of the Am. Soc. of Microbiology, and of Int. Society for the Study of Xenobiotics.
Back to Scientific Advisory Board
Brian Arenare, M.D., is currently providing consulting services to the pharmaceutical and healthcare industries. From January 1994 to August 1994, Dr. Arenare was the General Manager of Ropharmex U.S.A. Corp., which provides international pharmaceutical trade and consulting services. From February 1992 to February 1993, Dr. Arenare was a consultant with The Wilkerson Group, Inc., which provides strategic management consulting services to pharmaceutical and biotechnology companies. From January 1990 to January 1992, he was Managing Partner of AIM Consulting, which provided technical and strategy consulting to pharmaceutical companies. He has been an attending physician at the Beth Israel Medical Center in New York City since July 1993 and was an attending physician at Lenox Hill Hospital in New York City from January 1989 to December 1991. Dr. Arenare received his M.D. from Yale University in 1983 and an M.B.A. from Columbia University in 1992. Dr. Arenare was a director of the Company from 1994 to 1997.
Back to Scientific Advisory Board
Joan W. Bennett, Ph.D., is a specialist in the generic and secondary metabolism of filamentous fungi. A graduate of the University of Chicago, Dr. Bennett is currently a Professor in the Department of Cell and Molecular Biology at Tulane University in New Orleans, Louisiana. Active in a number of professional societies, she has been Vice President of the British Mycological Society, a Board member of the Society for Industrial Microbiology, and is a Past President of the American Society for Microbiology. She is currently co-editor of The Mycota and Advances in Applied Microbiology, an Associate Editor of Mycologia, and Mycology Series Editor for Marcel Dekker. She has co-edited six books, and published well over 100 research papers, chapters and reviews.
Back to Scientific Advisory Board
William T. Bradner, Ph.D., is an Adjunct Professor for the Departments of Chemistry and Biology at Syracuse University and is also the President of Research Advisors, an independent consulting firm. Dr. Bradner has published over 194 articles, book chapters, abstracts, and patents. He was previously Director of Administration and Deputy Director of Preclinical Anti-Cancer Research at Bristol-Myers Squibb. Dr. Bradner received his Ph.D. from Lehigh University in 1952.
Back to Scientific Advisory Board
Geoffrey A. Cordell, Ph.D., is a Professor and Department Head of the Medicinal Chemistry and Pharmacognosy Department at The College of Pharmacy, University of Illinois at Chicago. He has lectured throughout the world on the isolation of biologically active natural products and has received various fellowships and awards. He has published over 460 scientific papers and reviews. He received his Ph.D. in organic chemistry from the University of Manchester in 1970.
Back to Scientific Advisory Board
Sukh Dev, Ph.D., D.Sc., F.N.A., is a visiting Professor at the B.R.A. Centre for Biomedical Research, University of Delhi, India and has studied the organic chemistry of natural products and Ayurvedic medicinal plants for more than 40 years. He has held Research Professorship at the Indian Institute of Technology in Delhi (1988 - 1992), Director of the Malti-Chem Research Center in Baroda, India (1974 - 1988) and has been a Visiting Professor at the Stevens Institute of Technology, the University of Georgia, and the University of Oklahoma. He is a recipient of several awards including the Ernest Guenther Award (1980) of the American Chemical Society, and the Third World Academy of Sciences Award in Chemistry (1988). He has published over 350 scientific papers, books, and chapters and holds over 50 patents. He received his Ph.D. and D.Sc. from the Indian Institute of Science in 1948 and 1960, respectively.
Back to Scientific Advisory Board
Sun Han-Dong, Ph.D., is a professor at the Kunming Institute of Botany, the Academy of Sciences of China. He was previously the Director of the Kunming Institute of Botany. Dr. Han-Dong is known for his academic achievements on ent-kauranoids, cumarins, and phenolic constituents from lichens. He has published over 300 papers and received nineteen awards in the People's Republic of China for his research achievements, including the Second and Third Award of Science and Technology from the Academy of Sciences of China and Yunnan Province and the First Award of Science and Technology of Kunming City.
Back to Scientific Advisory Board
Allen I. Laskin, Ph.D., is President of Laskin/Lawrence Associates. He has previously served as the Vice President of Research and Development and Chief Scientific Officer of Ethigen Corporation and President of Matrix Research Laboratories. Among his honors, Dr. Laskin has received the Charles Thom Research Award, presented by the Society for Industrial Microbiology. His work in microbial transformations of steroids led to two dozen patents and a number of publications while working at the Squibb Institute for Medical Research between 1962 and 1969. Dr. Laskin is Senior Editor of The Journal of Industrial Microbiology and Co-Editor of Advances in Applied Microbiology. Dr. Laskin received his Ph.D. from the University of Texas in 1956.
Back to Scientific Advisory Board
Zhang Li-He, Ph.D., is Professor and Dean of the School of Pharmaceutical Sciences at Beijing Medical University of the People's Republic of China. He has studied for over two decades the chemistry of nucleosides, nucleotides, and anti-tumor and anti-viral drugs and has published over 130 scientific papers in these areas. He has been a recipient of the National Scientific Research Excellence Award from the Science and Technology Commission and The Ministry of Education of the People's Republic of China and the Science and Technology Prize of Beijing from the Beijing Government. He received the Otani Prize and an honorary Ph.D. from Hoshi University, Japan in 1988 and 1990, respectively. He was awarded the 12th Edgar Snow Professorship by the University of Missouri-Kansas City, USA in 1993.
Back to Scientific Advisory Board
Renuka Misra, Ph.D., is currently the Director of Natural Products at the Company and she is a guest research scientist/consultant at NIH engaged in the study of natural products, including Ayurvedic plant substances and their anti-aging and memory enhancing activities. She has studied the chemistry of bioactive natural products for over two decades. She previously worked at a number of research centers including the University of Nebraska, North Carolina State University, the University of Toronto, the University of Illinois, John Hopkins University and the NCI-Frederick Facility. Dr. Misra received her Ph.D. from the National Chemical Laboratory, Poona, India in 1965.
Back to Scientific Advisory Board
Lester A. Mitscher, Ph.D. is currently the University Distinguished Professor and former Chairman of the Department of Medicinal Chemistry at the University of Kansas, one of the nation=s premier research institutions for chemistry. Among his past accomplishments, he has served on the Senior Advisory Council of G.D. Searle & Co., and has been the Chairman of the Biological and Natural Products Study Section for the NIH, as well as Chairman of the American Society for Pharmacognosy. Dr. Mitscher received his Ph.D. from Wayne State University in 1968. Dr. Mitscher was a director of the Company from 1994 to 1997.
Back to Scientific Advisory Board
Otto J. Plescia, Ph.D., Professor Emeritus of Immunology, Waksman Institute, Rutgers University, is currently Adjunct Professor of Medical Microbiology & Immunology at the University of South Florida, College of Medicine, Tampa, Florida. His main research interests relate to the pathogenesis of virus and cancer induced immunodeficiency, and the development of immunomodulating drugs to treat such immunodeficiencies. He has served on the Advisory Boards of several immunological journals, is a member of the American Association of Immunologists and other professional societies, and has published extensively on the subject of acquired immunodeficiency. He received his Ph.D. from Cornell University in 1947.
Back to Scientific Advisory Board
C. L. Propst, Ph.D., is President and CEO of the Texas Biotechnology Foundation. Previously she was Founder and Executive Director of the Center for Biotechnology, and Director of the Graduate Program in Biotechnology, at Northwestern University. She has also served as President and CEO of Affiliated Scientific, Inc., as Corporate Vice President, Research and Development Worldwide for Flow General, Inc., as Divisional Vice President, Research and Development for Ayerst Laboratories, American Home Products, and as Head of Microbial and Molecular Biology for Abbott Laboratories. Dr. Propst received her Ph.D. from Yale University in 1973.
Back to Scientific Advisory Board
Xechem Locations
Corporate Headquarters
Xechem International, Inc. New Brunswick Technology Center 100 Jersey Avenue Building B, Suite 310 New Brunswick, NJ 08901 USA
(Xechem, Inc., Xechem Laboratories, Inc., and XetaPharm, Inc. are also located at the above address) Tel: (732) 247-3300 Fax: (732) 247-4090 E-Mail: xechem*erols.com
Regional Office
Xechem/XetaPharm, Inc. 12106 Pawnee Drive Gaithersburg, MD 20878 USA Tel: (301) 330-5098 Fax: (301) 330 5098 E-Mail: xechem-reg*hotmail.com
Xechem Nigeria
Xechem Pharmaceuticals Nigeria Ltd. Sheda Science and Technology Complex Technology Park, Gwagwalada Federal Capital Territory, Abuja NIGERIA http://xechemnigeria.org Tel: 234-9-671-8379 E-Mail: xechemnigeria*yahoo.com
Xechem U.K.
Xechem U.K., Ltd. The White House 2 Meadrow Godalming Surrey GU7 3HN UK Tel: 44 (0) 1483 424 269 Fax: 44 (0) 1483 424 310
Xechem India
Xechem (India) Pvt. Ltd. B-3/17, Safdarjung Enclave New Delhi 110029 INDIA Tel: 011-91-11-2-618-4293 Tel: 011-91-11-2-618-4294 Fax: 011-91-11-2-618-4295 Email: xechem*bol.net.in
XetaPharm (Xechem Nutraceutical Subsidiary)
Nutraceutical Products With Pharmaceutical Quality Standards
Over the past several years there has been a growing awareness of alternative medicines. This was recognized by the U.S. Federal government and an Office of Alternative Medicine was established within the National Institute of Health (NIH).
The Gold Leaf is our symbol for purity, quality and reliability.
Based upon the analytical and technological strengths of Xechem in the areas of natural products, our XetaPharm subsidiary, formed in 1996, is producing over the counter (OTC) natural products such as Melatonin, DHEA, GinsengOnce®, GinkgoOnce®, GarlicOnce®, Gugulon™, Co-Enzyme Q-10 and other life enhancing nutritionals from China, Mexico, South America, India and other places around the world.
The same exacting quality standards apply for botanicals, herbals and nutritional supplements as for pharmaceuticals. Products are standardized, with potency and purity verifiable by an outside independent laboratory. Products contain pharmaceutical grade-active ingredients (United States Pharmacopoeia [USP] grade when applicable). Finished products are tested for potency, purity, weight variation, disintegration, and dissolution as per USP.
To directly link to our separate XetaPharm website, click below to transfer: www.XetaPharm.com
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
![[Wink]](wink.gif)
![[Big Grin]](biggrin.gif)
